1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Clinical Research Network on Antimicrobial Resistance (AMR) (RFA-AI-27-005) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). NIAID seeks to continue support for a Clinical Research Network on Antimicrobial Resistance (AMR) to design, implement, and manage clinical research addressing key clinical questions in AMR.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Clinical Research Network on Antimicrobial Resistance Clinical Research Network on Antimicrobial Resistance Agency: National Institutes of Health Assistance Listings: 93. 855 -- Allergy and Infectious Diseases Research Last Updated: May 13, 2026 View version history on Grants.
gov The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by continuing support for a Clinical Research Network on Antimicrobial Resistance (AMR). AMR is a major health challenge that limits treatment options and allows resistant infections to persist.
Individuals with chronic conditions like diabetes and cancer are particularly vulnerable, resulting in increased illness and death as well as higher healthcare costs in the United States. The program aims to design, implement, and manage clinical research addressing key clinical questions in AMR. Research will focus on bacterial and fungal infections associated with AMR.
Areas of emphasis include clinical testing of new antibiotics and other treatments such as bacteriophage therapy, methods optimizing the use of existing antibiotics, evaluating novel diagnostic tests including using diagnostics to refine treatment strategies, and mentoring the next generation of AMR clinical researchers.
Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) For-profit organizations other than small businesses Special district governments City or township governments Public and state institutions of higher education Private institutions of higher education Other Eligible ApplicantsFaith-based or Community-based Organizations;Regional Organizations Grantor contact information Division of Microbiology and Infectious Diseases Please contact via e-mail.
AMRClinicalResearchNetworkContact@mail. nih. gov AMRClinicalResearchNetworkContact@mail.
nih. gov No documents are currently available. Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Eligible applicants include various non-profit organizations, businesses (for-profit and small businesses), government entities, and higher education institutions. Confirm the full requirements in the official notice before applying.
The current listing shows $15,000,000 (total program). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Clinical Research Network on Antimicrobial Resistance (AMR) (RFA-AI-27-005) are due September 29, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Clinical Research Network on Antimicrobial Resistance (AMR) (RFA-AI-27-005) is funded by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Research on Short-Lived and Long-Lived Plasma Cells in Humans is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). This topic encourages applications to understand the biology of Short-Lived Plasma Cells (SLPC) and Long-Lived Plasma Cells (LLPC) through characterization of plasma cell phenotypes and function in human health and disease.
NIAID Career Transition Award (K22) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). This award provides support for investigators transitioning from a mentored postdoctoral research position to an independent faculty position. It aims to bridge the gap between mentored and independent research, with a focus on immunology and infectious diseases.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
OMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read articleNIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read articleNIH committed $402 million across 601 multiyear-funded grants in the first eight months of FY 2026 — more than four times the pace of two years ago. The mechanism front-loads obligations into a single fiscal year, leaving less budget for new project starts and squeezing FY 2026 success rates. What researchers and institutions should be doing now.
Read article